Specialty Pharmacy, Infusion M&A Activity Is Slowing Down
The level of merger and acquisition (M&A) activity within the specialty pharmacy and home infusion arenas that has been occurring for numerous years has certainly depleted the number of companies available for deals. But that’s not to say they aren’t happening. Last month, Shields Health Solutions unveiled a deal to acquire ExceleraRx Corp. (see story, p. 7). And approximately one month ago, Centene Corp. acquired PANTHERx Rare, LLC, and revealed a deal to acquire Magellan Health, Inc. (RSP 1/21, p. 1). AIS Health spoke with Bill Bolding, a senior analyst for Provident Healthcare Partners, and Michael Patton, managing director at the firm, to get their perspective on M&A trends within those industries.
AIS Health: Did you notice any COVID-spurred M&A activity last year?
Related Posts

Study Finds Fertility Program Prevents Medication Waste, Loss, Missed Doses
READ MORE
New FDA Approvals: FDA Expands Patient Population of Takeda’s HyQvia
READ MORE